The aim of this study was to clarify the ability of KIF2C to enhance cancer cell viability, proliferation and invasion in NSCLC by activating the AKT-GSK3β-β-catenin pathway. The gene discussed is KIF2C; the disease is non-small cell lung carcinoma.